In vitro release - In vivo microbiological and toxicological studies on ketoconazole lipid granules

Pharmaceutical Development and Technology

Volumn 12, Issue 6, 2007, Pages 581-590

  Ozyazici, Mine ^a   Gokce, Evren Homan ^a   Ozer, Ozgen ^a   Ay, Zeynep ^a   Guneri, Tamer ^a   Ertan, Gokhan ^a   Gokce, Goksel ^a   Metin, Dilek Yesim ^a   Hilmioglu, Suleyha ^a   Durmaz, Guliz ^a   Yalcin, Ayfer ^a   Pekcetin, Cetin ^b   Ozyurt, Dogan ^b  

^a EGE UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Antacid; Drug release; Hepatotoxicity; Ketoconazole; PEG; Vulvo vaginal candidiasis

Indexed keywords

ANTACID AGENT; GLUTATHIONE; GLYCEROL BEHENATE; KETOCONAZOLE; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG GRANULE; DRUG RELEASE; DRUG SOLUBILITY; EVALUATION; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; LIVER; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; MICROBIOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STOMACH; SUSTAINED DRUG RELEASE; TABLET FORMULATION; THERAPY EFFECT; TOXICOLOGY; VAGINA; VAGINA CANDIDIASIS;

ALUMINUM HYDROXIDE; ANIMALS; ANTACIDS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; DELAYED-ACTION PREPARATIONS; DRUG ANTAGONISM; EXCIPIENTS; FATTY ACIDS; FEMALE; GLUTATHIONE; GLYCEROL; KETOCONAZOLE; LIVER; MAGNESIUM HYDROXIDE; MICE; POLYETHYLENE GLYCOLS; STOMACH; TABLETS; VAGINA;

EID: 37549035942     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450701560968     Document Type: Article

References (40)

1. Mooter, G.; Wuyts, M.; Blaton, N.; Busson, R.; Grobet, P.; Augustijns, P.; Kinget, R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone. Eur. J. Pharm. Sci. 2001, 12, 261-269.
2. Skiba, M.; Lahiani, M.S.; Marchais, H.; Duclos, R.; Arnaud, P. Stability assessment of ketoconazole in aqueous formulations. Int. J. Pharm. Sci. 2000, 198, 1-6.
3. Strandberg, T.E.; Tilvis, R.S.; Miettinen, T.A. Effects of ketoconazole on cholesterol synthesis and precursor concentrations in the rat liver. Lipids 1987, 22, 1020-1024.
4. Rodriguez, R.J.; Acosta, D. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997, 117, 123-131.
5. Yuen, K.H.; Peh, K.K. Simple high-performance liquid chromatographic method for determination of ketoconazole in human plasma. J. Chromatogr. B 1998, 715, 436-440.
6. Reynolds, J.E.F. The complete drug reference. In Martindale, The Extra Pharmacopoeia; 32nd Ed.; Porf tt, K., Eds.; Pharmaceutical Press: London, 1999, 367-384.
7. Cordoba-Diaz, D.; Cordoba-Diaz, M.; Awad, S.; Cordoba-Borrego, M. Effect of pharmacotechnical design on the invitro interaction of ketoconazole tablets with non-systemic antacids. Int. J. Pharm. 2001, 226, 61-68.
8. Jackson, K.; Young, D.; Pant, S. Drug-excipient interactions and their effect on absorption. Pharm. Sci. Technol. Today 2000, 10, 336-345.
9. Saraiya, D.; Bolton. D. The use of precirol to prepare sustained release tablets of theophylline and quinidine gluconate. Drug Dev. Ind. Pharm. 1990, 16, 1963-1969.
10. Hamdani, J.; Moes, A.J.; Amighi, K. Physical and thermal characterization of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int. J. Pharm. 2003, 260, 47-57.
11. Hite, M.; Turner, S.; Federici, C. Oral delivery of poorly soluble drugs. Part 2. Formulation strategies for solid dosage forms and novel delivery systems for controlled release. Pharmaceutical Manufactoring and Packing Sorcer, 2003.
12. Barthelemy, P.; Laforet, J.P.; Farah, N.; Joachim, J. Compritol 888 ATO: An innovative hot-melt coating agent for prolonged-release drug formulations. Eur. J. Pharm. Biopharm. 1999, 47, 87-89.
13. Intini, G.; Aguirre, A.; Bobek, A. Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis. Int. J. Antimicrob. Agents 2003, 22, 594-600.
14. Fidel, P.L.; Cutright, J.L.; Sobel, J.D. Efficacy of D0870 treatment of experimental candida vaginitis. Antimicrob. Agents Chemother. 1997, 9, 1455-1459.
15. Karasulu, E.; Kirilmaz, L. In vivo evaluation of hydrodynamically balanced capsule with sustained-release of ketoconazole by means of noncompartmental pharmacokinetic analysis. In Proceedings of the Fifth European Congress of Biopharmaceutics and Pharmacokinetics; Aiache, J.M., Ed.; Brussels. Medecine et hygiene: Geneva; Eur. J. Drug Metab. Pharmacokinet., Special Issue, 1994 150-153.
16. Robinson, J.R.; Eriksen S.P. Theoretical formulation of sustained release dosage forms. J. Pharm. Sci. 1966, 55, 1254-1263.
17. Parrot, E.L. The effect of disintegrants and pH on disintegration of vaginal tablets. Indian Drugs 1988, 31, 122-124.
18. Gjellan, K.; Graffner, C. Comparative dissolution studies of rectal formulations using the basket, the paddle and the flow through methods. II. Ibuprofen in suppositories of both hydrophilic and lipophilic types. Int. J. Pharm. 1994, 112, 233-240.
19. Nobilis, M.; Pour, M.; Kunes, J.; Kopecky, J.; Kvetina, J.; Svoboda, Z.; Sladkova, K.; Vortel, J. High-performance liquid chromatographic determination of ursodeoxycholic acid after solid phase extraction of blood serum and detection-oriented derivatization. J. Pharm. Biomed. Anal. 2001, 24, 937-946.
20. Suresh, B.; Sriram, S.; Dhanaraj, S.A.; Elango, K.; Chinnaswamy, K. Anticandidal activity of Santolina chamaecyparissus volatile oil. J. Ethnopharmacol. 1997, 55, 151-159.
21. Bonhomme-Faivre, L.; Forestier, F.; Auchere, D.; Soursac, M.; Orbach-Arbouys, S.; Farinotti, R. Chronic administration of verapamil, ketoconazole and carbamazepine: Impact on immunological parameters. Int. J. Pharm. 2002, 238, 133-137.
22. Ozbek, E.; Turkoz, Y.; Sahna, E. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int. 2000, 85, 742-746.
23. Jollow, D.J.; Mitchell J.R.; Zampaglione, Y.; Gillete, J.R. Bromobenzene induced liver necrosis protective role of glutathione and evidence for bromobenzene oxide as the toxic metabolite. Pharmacology 1974, 11, 151-169.
24. Cornaire, G.; Woodley, J.; Hermann, P. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 2004, 278, 119-131.
25. Verma, R.K.; Garg, S. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J. Pharm. Biomed. Anal. 2004, 35, 449-458.
26. Meshali, M.M.; El-Sayed, G.M.; El-Aleem, H.M.A.; El-Said, Y. Optimisation of theophylline release from tablets containing Compritol. S.T.P. Pharm. Sci. 1995, 6, 429-434.
27. Mirghani, A.; Idkaidek, N. M.; Salem, M.S. Formulation and release behavior of diclofenac sodium in Compritol 888. Drug Dev. Ind. Pharm. 2000, 26, 791-795.
28. Jannin, V.; Bérard, V.; N'Diaye, A. Comparative study of the lubricant performance of Compritol 888 ATO either used by blending or by hot melt coating. Int. J. Pharm. 2003, 262, 39-45.
29. N'diaye, A.; Jannin, V.; Bérard, V. Comparative study of lubricant performance of Compritol HD 5 ATO and Compritol 888 ATO: Effect of polyethylene glycole behenate on lubricant capacity. Int. J. Pharm. 2003, 254, 263-269.
30. Hoeschele, J.; Roy, A.K.; Pecoraro, V.L.; Carver, P.L. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob. Agents and Chemother. 1994, 38, 319-325.
31. Ozguney, I.; Ertan, G.; Guneri T. Dissolution characteristics of megaloporous tablets prepared with two kinds of matrix granules. Il Farmaco, 2004, 59, 549-555.
32. Robinson, J.R.; Eriksen S.P. Theoretical approach to sustained-release multiple-dose therapy: Noncumulative attainment of desired blood level. J. Pharm. Sci. 1970, 59, 1796-1800.
33. Hardman, J.G.; Limbird, L.; Goodman, A. Imidazoles. In Goodman and Gilman's The Pharmacological Basis of Therapeutics; 10th Ed.; McGraw Hill Publishing: Nevada, 2005, 1301-1302, 1645.
34. Ozyazici, M.; Gokce, E.H.; Ertan, G. Release and diffusional modeling of metronidazole lipid matrices. Eur. J. Pharm. Biopharm. 2006, 63, 331-339.
35. Carlson, J.A.; Henry, J.M.; Canafax, D.M. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am. J. Hosp. Pharm. 1983, 40, 1334-1336.
36. Connors, R.D.; Elder, E.J. Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug Dev. Technol. 2004, 4, 245-249.
37. Price, J.C.; Gore, A.Y.; Chowhan, Z.; Holder, R.L. Polyethlene glycol. In Handbook of Pharmaceutical Excipients; The Pharmaceutical Press: London, 1986, 209-213.
38. Walsh, S.; Shah, A.; Mond, J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob. Agents Chemother. 2003, 47, 554-558.
39. Borysowski, J.; Weber-Dabrowska, B.; Górski, A. Bacteriophage endolysins as a novel class of antibacterial agents. EBM 2006, 231, 366-377.
40. Liu, R.; Choi, J. Age associated decline in gamma-glutamyl sisteine sentase gene expression in rats. Free Radic. Biol. Med. 2000, 28, 566-574.